Alto Neuroscience ANRO
$25.37 −$1.14 (-4.30%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $25.37 0.00%
Open$25.76
Prev close$26.51
Day range$24.40 – $26.48
Volume522.5K
Market cap$1.02B
P/E (TTM)–
Dividend yield–
ANRO Stock News
Headlines matching Alto Neuroscience or the ANRO ticker, most recent first.
- H.C. Wainwright Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Maintains Target Price $55
- H.C. Wainwright Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Raises Target Price to $55 Positive
- Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Alto Neuroscience, Inc. (ANRO) and Irhythm Technologies (IRTC)
- BofA Securities Maintains Alto Neuroscience(ANRO.US) With Buy Rating
- BTIG Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Maintains Target Price $37
- BTIG Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Raises Target Price to $37 Positive
- Alto Neuroscience, Inc. (ANRO) Receives a Buy From Jefferies
- Jefferies Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Raises Target Price to $40 Positive
- Analysts Offer Insights on Healthcare Companies: Alto Neuroscience, Inc. (ANRO) and Owlet (OWLT)
- Analysts Offer Insights on Healthcare Companies: Oruka Therapeutics (ORKA), Alto Neuroscience, Inc. (ANRO) and Astrana Health (ASTH)
- BTIG Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Maintains Target Price $28
- Analysts Offer Insights on Healthcare Companies: TransMedics Group (TMDX), Aquestive Therapeutics (AQST) and Alto Neuroscience, Inc. (ANRO)
- JonesTrading Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Maintains Target Price $44
- H.C. Wainwright Remains a Buy on Alto Neuroscience, Inc. (ANRO)
- H.C. Wainwright Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Maintains Target Price $50
No comments yet — be the first to weigh in on ANRO.
Sign in to join the discussion.